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ABSTRACT
The rapid spread of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 has
raised questions about Fabry disease (FD) as an independent risk factor for severe COVID-19 symptoms. Available real-
world data on 22 patients from an international group of healthcare providers reveals that most patients with FD
experience mild-to-moderate COVID-19 symptoms with an additional complication of Fabry pain crises and transient
worsening of kidney function in some cases; however, two patients over the age of 55 years with renal or cardiac disease
experienced critical COVID-19 complications. These outcomes support the theory that pre-existent tissue injury and
inflammation may predispose patients with more advanced FD to a more severe course of COVID-19, while less advanced
FD patients do not appear to be more susceptible than the general population. Given these observed risk factors, it is best to
reinforce all recommended safety precautions for individuals with advanced FD. Diagnosis of FD should not preclude
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providing full therapeutic and organ support as needed for patients with FD and severe or critical COVID-19, although
a FD-specific safety profile review should always be conducted prior to initiating COVID-19-specific therapies. Continued
specific FD therapy with enzyme replacement therapy, chaperone therapy, dialysis, renin–angiotensin blockers or
participation to clinical trials during the pandemic is recommended as FD progression will only increase susceptibility to
infection. In order to compile outcome data and inform best practices, an international registry for patients affected by
Fabry and infected by COVID-19 should be established.
Keywords: chloroquine, COVID-19, enzyme replacement therapy, Fabry disease, lysosome, pathogenesis, prevention,
SARS-CoV-2
INTRODUCTION
Fabry disease (FD; OMIM #301500) is a progressive, multisyste-
mic, X-linked genetic disease caused by pathogenic variants in
the GLA gene encoding the a-galactosidase enzyme [1]. Deficient
a-galactosidase enzyme activity leads to progressive storage of
glycosphingolipids, particularly globotriaosylceramide (Gb3/GL3)
and its deacylated derivative globotriaosylsphingosine (lysoGb3/
lysoGL3), resulting in a cascade of pathogenic effects including
cellular dysfunction and demise, vascular injury, inflammation
and tissue fibrosis. When a-galactosidase activity is severely de-
ficient, it results in classic FD, a childhood-onset multisystemic
disorder with reduced life expectancy in untreated patients, ow-
ing to cardiac complications, end-stage renal disease and stroke
[1]. Nonclassic or later-onset FD arises in patients with some re-
sidual enzyme activity; it is still life-impacting but is character-
ized by a more variable disease course, in which onset is post-
childhood and the main disease manifestations may be limited
to a single organ [2, 3].
The rapid spread of coronavirus disease 2019 (COVID-19) in
2020 caused by the severe acute respiratory syndrome coronavi-
rus 2 (SARS-CoV-2) has raised concerns about the possible in-
creased risk for severe COVID-19 complications in patients with
FD and the adverse effects of drugs used for COVID-19 on
patients with FD, and speculations on the interaction of drugs
used for FD with COVID-19. The purpose of this article is to re-
port the experience of an international group of experts on out-
comes and provision of medical care to patients with FD during
the first wave of the COVID-19 pandemic, and to use these real-
world data to give consensus recommendations for the man-
agement and treatment of patients with FD during the forth-
coming waves of the COVID-19 pandemic [see, Box 1].
CLINICAL SPECTRUM OF COVID-19
The clinical spectrum of COVID-19 is extremely variable rang-
ing from completely asymptomatic or flu-like symptoms to le-
thal pneumonia, sepsis and multi-organ failure including
respiratory failure, heart failure, acute renal injury and coagul-
opathy. The World Health Organization (WHO) categorizes
symptoms into disease severity categories of mild, moderate,
severe and critical [4] (Table 1). The calculated incidence of
each category depends on local testing policies. When all ex-
posed individuals are tested, irrespective of clinical symptoms,
the case and infection fatality rates have been estimated
around 2.6% [95% confidence interval (CI) 0.89–6.7] and 1.3%
(95% CI 0.38–3.6), with asymptomatic infections occurring in
around 45% of infected individuals, more frequently in the
young and in females [5–7]. Mortality may increase in high-risk
individuals, when no advanced healthcare is provided or when
healthcare services are saturated, limiting access to organ sup-
port systems.
RISK FACTORS FOR CRITICAL COVID-19
DISEASE
Risk factors for critical COVID-19 disease identified in the gen-
eral population include older age, male sex and the presence of
comorbidities such as obesity, hypertension, diabetes, chronic
kidney disease (CKD), cardiovascular disease, chronic lung dis-
ease, cancer, neurological conditions, immunocompromising
conditions and smoking (Supplementary data, Table S1) [8–13].
Some of these risk factors overlap with symptoms seen in adult
patients with FD including cardiac complications, renal disease,
pulmonary disease and strokes (Figure 1).
RATIONAL FOR THE CONCERNS REGARDING
COVID-19 IN PATIENTS WITH FD: POTENTIAL
OVERLAP BETWEEN THE RESPECTIVE
PATHOGENESIS AND TARGET ORGANS
Four key features contributed to the severe pathogenesis of
COVID-19 [14]. First, cellular infection is dependent on a high-
level expression of angiotensin-converting enzyme 2 (ACE2) at
the plasma membrane, as found in type II pneumocytes, endo-
thelial cells, tubular epithelial cells, and cardiac and gastroin-
testinal cells, which may explain the multi-organ dysfunction
[15–19]. Second, the inflammatory response may be extremely
severe, with an excessive release of cytokines (‘cytokine storm’),
causing endothelial and organ injury by itself. Third, a pro-
thrombotic state driven by inflammation and endothelial cell
injury, which may lead to micro- or macrothrombosis, including
pulmonary thromboembolism, myocardial infarction and
stroke. Fourth, hypoxemia due to lung involvement and hemo-
dynamic instability are thought to contribute to tissular injury
during COVID-19 (Supplementary data, Figure S1B).
The pathogenesis and target organ injury of COVID-19 are
common to or partly overlap with those of FD (Figure 1), raising
theoretical concerns that the pre-existing FD pathology may
serve as a ‘first hit’ that increases patients’ risk for serious com-
plications when infected by COVID-19.
Specifically, endothelial cell Gb3/GL3 storage is a hallmark of
FD, and endothelial dysfunction and thrombophilia have been
proposed among the mechanisms underlying vascular involve-
ment in patients with classic FD [20]. Plasma levels of soluble
vascular cell adhesion molecule-1 (VCAM-1), a cell adhesion
molecule that contributes to leukocyte recruitment into vessel
walls, are significantly elevated in FD [20], and the VCAM1 gene
is overexpressed in COVID-19 lungs [21]. Since COVID-19 results
in distinctive vascular features in the lungs, consisting of severe
endothelial injury associated with the presence of intracellular
virus, disrupted cell membranes, widespread thrombosis with
microangiopathy and increased angiogenesis, classically
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affected patients with FD may be at particularly high risk for the
vascular COVID-19 complications [20–22].
Assessing the risk of severe COVID-19 in patients
with FD
Combining real-world data with the known pathogenesis of FD
and the general population risk factors for severe complications
from COVID-19 provides a window into the incidence and im-
pact in this population. In the experience of the French national
referral center for FD, 9 out of 217 patients (4.2%) were infected
by SARS-CoV-2, including 4 during the first wave (March to May
2020), and recovered without any specific treatment except for
the most advanced patient who required 1-week hospitalization
and oxygen during transient deterioration of his kidney func-
tion. A published case series from Italy found that none of their
129 patients with FD were diagnosed with COVID-19, although
three patients did have flu-like symptoms and self-quarantined
[23]. The majority of treated patients in Italy continued their en-
zyme replacement therapy (ERT) with the only exceptions being
three individuals that refused to receive home infusions [23].
The heterogeneity in clinical presentation among patients with
FD was reminiscent of that observed in the general population.
This information suggests that the risk for life-threatening com-
plications depends on the progression of FD in the individual
patient. Accordingly, the specific discussion and data in this
article are divided into two groups, uncomplicated FD (those
without organ disease progression) and advanced FD to com-
pare theoretical risk on real-life impact (Table 2 and Figure 2). In
this publication, we report data on 22 patients with FD to pro-
vide real-world experience with COVID-19 infection in patients
with FD (Table 3).
The available international dataset includes 15 patients
with uncomplicated FD and 7 patients with advanced FD
(Table 3).
Patients with uncomplicated FD. While FD is primarily a genetic
lysosomal storage disease, an inflammatory component has
also been proposed on the basis of increased inflammatory
markers possibly contributing to organ damage and loss of
function [24]. To date, there are no studies of COVID-19 in
patients with FD, but the overlap in impacted organ systems
and the involvement of inflammation may place patients with
FD at higher risk for complications compared with age- and sex-
matched people who do not have FD. This is of particular con-
cern for risk of acute deterioration in cardiac function, stroke
risk, acute kidney injury and possibly the cytokine storm [25].
Some symptoms of uncomplicated FD may be exacerbated
by COVID-19. A hallmark of classic FD is increased burning neu-
ropathic pain seen prior to and during illness and fevers [3, 26,
27]. In those experiencing this feature, infection with SARS-
Table 1. WHO COVID-19 disease severity categories
Severity category Key feature Age group Description
Mild disease N/A All ages Symptomatic patients without evidence of viral pneumonia or hypoxia
Moderate disease Pneumonia All ages Clinical signs of nonsevere pneumonia without features of severe
pneumonia
Severe disease Severe pneumonia Pediatric Clinical signs of pneumonia plus one of the following:
• Central cyanosis or SpO2<90%,
• Severe respiratory distress
• General danger signs (inability to breastfeed or drink; lethargy,
unconsciousness or convulsions) OR fast breathing (in breaths/min)
Adolescent/adult Clinical signs of pneumonia plus one of the following:
• Respiratory rate > 30 breaths/min
• SpO2<90% on room air
• Severe respiratory distress
Critical disease Acute respiratory
distress syndrome
All ages Onset within 1 week of known clinical insult or worsening respiratory
symptoms not explained by cardiac failure or fluid overload
Sepsis Pediatric Symptoms and or signs of COVID-19 infection and >2 age-based SIRS criterion
of which one must be abnormal temperature or white blood cell count
Adolescent/adult Acute life-threatening organ dysfunction caused by a dysregulated host immune
response to suspected or proven COVID-19 infection
Septic shock Pediatric Any hypotension or two or three of the following:
• Altered mental status
• Bradycardia or tachycardia
• Prolonged capillary refill or weak pulse
• Fast breathing
• Mottled or cool skin or petechial or purpuric rash
• High lactate
• Reduced urine output
• Hyperthermia
• Hypothermia
Adolescent/adult Persistent hypotension despite volume resuscitation, requiring
vasopressors to maintain MAP >66 mmHg and serum
lactate level >2 mmol/L
SIRS, systemic inflammatory response syndrome; MAP, mean arterial pressure.
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CoV-2 may be heralded by increased pain. Three patients with
uncomplicated FD did report pain crisis with fever, complicating
otherwise mild COVID-19 disease. Patients with FD may also ex-
perience gastrointestinal complications including diarrhea,
nausea, vomiting and abdominal pain [26, 28]. Four patients
with uncomplicated FD did report increased abdominal pain
and/or diarrhea as symptoms associated with COVID-19. As a
subset of COVID-19, patients develop gastrointestinal symp-
toms in addition to the typical respiratory illness; this may also
exacerbate underlying FD gastrointestinal symptoms that may
require management in a medical setting to avoid dehydration
and severe ongoing pain [29, 30]. One uncomplicated FD patient
was hospitalized for observation and received intravenous
(IV) fluids to treat dehydration and pain crisis (Table 3).
Advanced FD. FD exhibits a high phenotypic variability with a
wide clinical spectrum influenced by the nature of the GLA vari-
ant and the level of residual a-galactosidase among other fac-
tors [29–31]. Although as a multisystemic disease, FD typically
attacks key organs in tandem resulting in a complex manage-
ment challenge, this article handles each organ system individ-
ually, recognizing that the risks will be cumulative. Patients
with advanced FD should be considered a high-risk population,
regardless of age. The most severely affected patients do have
multiple known risk factors related to renal, cardiac and/or pul-
monary disease, immunosuppression following transplant and
stroke, which have been identified risk factors of poor outcome
in case of COVID-19 [32].
Cardiac disease. Patients with FD may be at an increased risk of
cardiovascular morbidity and mortality during SARS-CoV-2 in-
fection, especially in advanced Fabry characterized by cardio-
myopathy and malignant arrhythmia [33–37]. In COVID-19,
myocardial damage, including fulminant myocarditis with cir-
culatory failure, is a cause of death [38]. Cardiac disease in FD is
associated with vascular dysfunction, oxidative stress, cytoskel-
etal remodeling, inflammation and fibrosis [24, 39, 40, 41] This
pre-existent cardiovascular injury may predispose patients
H+
Fabry disease
Severe in males More severe in males







Potentially severe heart and
cardiovascular disease;
potentially moderate lung disease
Systemic inflammation
Gastrointestinal and skin disease
Lysosomal lumen acid pH promotes fusion of
the endosome membrane with the virus envelope,
releasing the nucleocapsid into the cytoplasm
COVID-19 drugs (e.g. chloroquine/
hydroxychloroquine) cause lysosomal injury
Pre-existing cardiovascular and
lung disease increase severity
Causes potentially lethal cardiovascular
 and lung disease
COVID-19 drugs (e.g. chloroquine/
hydroxychloroquine) may cause severe
arrhythmia
Pre-existing kidney disease increases severity
Potentially severe kidney disease
Endothelial dysfunction,
micro and macrothrombosis
Systemic inflammation and hyperinflammation
Gastrointestinal and skin disease
FIGURE 1: Common features in the pathogenesis and clinical manifestations of FD and COVID-19. Attribution of parts of the image: Wolfdog406 at English Wikipedia;
Author: Peter van Driel, NL.
Source: https://thenounproject.com/search/? q¼kidney&i¼524431
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with FD to more severe cardiovascular COVID-19 manifestations
as seen in Patients #5, #8 and #15 in Table 3.
Chronic kidney disease. FD causes a proteinuric nephropathy that
may need renal replacement therapy (RRT; dialysis or trans-
plantation) at a mean age of 40 years [42, 43]. Individuals with
CKD, particularly those on RRT, are at higher risk of severe or
critical COVID-19 and death [8, 44]. Additionally, they are at
higher risk of acute-on-chronic renal injury, a frequent occur-
rence in patients with COVID-19, particularly at the time of intu-
bation, with the need for dialysis, a major poor prognostic factor.
A further potential issue is that COVID-19 may cause special
forms of focal and segmental glomerulosclerosis (FSGS), espe-
cially in African-Americans carrying specific APOL1 alleles [45].
Thus, COVID-19 may potentially aggravate podocyte injury and/
or accelerate the FSGS observed in FD. Patients with FD and
COVID-19 should be monitored for this possibility.
Neurologic complications. Cerebrovascular complications in FD in-
clude acute ischemia (small and large vessel stroke), hemor-
rhage and chronic cerebrovascular disease [46]. Ischemic stroke
has been reported as a frequent complication in COVID-19
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especially
in older males
Moderate Social distancing, hand hygiene
and outside surgical masks as
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err on prudent side and do as









Higher High Enhanced social distancing,
hand hygiene and surgical
or ideally FPP2/N95 masks at
home (if not living alone)
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Transplantationc Highest Highest Shielding at home using FPP2/N95
face masks if not living alone;
hand higiene




aFD with no existing end organ damage (kidney, heart, lung, central nervous system).
bCKD (pathological albuminuria >30 mg/g urinary creatinine) or eGFR <60 mL/min/1.73 m2) or arrhythmia or severe left ventricular hypertrophy/cardiomegaly or stroke
or decreased FEV1.
cAssumed to be on immune suppressants.
RAS either ACEis or ARBs. eGFR, estimated glomerular filtration rate.
Based on target organ injury Based on age and sex
• Stroke/TIA
• WML
• Other Fabry patients Risk of severe
COVID-19
• Kidney or heart
  transplant recipients
• Dialysis or advanced




  target organ injury
• Classic, no target
  organ injury
• Late onset, no target
  organ injury
• Classic males > age 40
• Classic females with severe renal/cardiac disease
• Non-classic/late-onset males and females
  with significant renal/cardiac disease
• Classic females > age 40
• Non-classic/late onset females
  > age 55 years
• Young non-classic/late-onset males
• Young classic females without evidence
  of disease but with comorbidities
• Young late onset
• Young classic females
  without evidence of disease
FIGURE 2: Risk of severe or critical COVID-19 in patients with FD. Given the scarcity of Fabry-specific information, this figure has extrapolated knowledge from the gen-
eral population and the natural history of FD [1, 2]. It shows two scales, depending on whether data are available for specific patients on the extent of target organ in-
jury. When this is known, the ‘Based on target organ injury’ scale should be used. When this is unknown, the ‘Based on age and sex’ scale provides some guidance.
TIA, transient ischaemic attack; WML, white matter lesion; LVH, left ventricular hypertrophy.
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patients [47]. Due to possible common pathogenetic mecha-
nisms, clinicians should be aware that patients with FD may be
potentially at a major risk for stroke manifestation as a COVID-
19 complication [48]. Stroke in patients with FD and COVID-19
should be treated with acute therapy and secondary prevention
therapy [48, 49]. Furthermore, more recent data indicate that
neurological manifestations in patients with COVID-19 may
have a broader spectrum, including PNS involvement (there are
emerging reports of Guillain–Barré syndrome) [47].
Neuropsychiatric manifestations. Depression develops in up to 46%
of patients with FD and is frequently associated with pain [49–
51]. Depression, anxiety and post-traumatic stress disorder can
be also be found with increased frequency in patients with
COVID-19 and individuals in the general population in response
to enforced lockdown and stress due to the pandemic [52–54].
Clinicians taking care of patients with FD and COVID-19 should
monitor carefully and manage mood changes of their patients,
since long-term post-traumatic stress disorder has been recog-
nized in Middle East respiratory syndrome coronavirus survi-
vors in Korea [55]. Anxiety, depression or fear of entering an
infusion center also can lead to an arbitrary cessation of ERT in
patients with FD.
Transplant. Patients with FD with advanced disease may have
received a kidney or heart transplant. Organ transplant recipi-
ents on immune suppressants should be considered at an in-
creased risk of severe or critical COVID-19 and early reports
support this heightened risk, with mortality rates in immuno-
suppressed patients around 25–30% [56]. The risk is likely higher
in the early post-transplant period when immune suppressant
dose is higher. Many centers have temporarily discontinued
transplant programs in the more active phase of the epidemic
and slowly resumed them once medical supplies and care cir-
cuits could be re-established safety [56]. All transplant patients
with COVID-19 should be admitted to hospital as they may pre-
sent with milder symptoms that progress rapidly resulting in
increased risk for unanticipated death at home [56]. However,
emphasis should be placed on prevention. Routine shielding
and use of N95/FPP2 face masks are recommended on top of
other preventive measures (Figure 1).
Pulmonary disease. Patients with FD may have silent or overt pul-
monary involvement, putting them potentially at increased risk
of severe or critical COVID-19 pulmonary manifestations, the
most common cause of death in COVID-19 patients. Symptoms
and signs of pulmonary involvement include dyspnea, wheez-
ing and dry cough [57]. The proposed mechanisms for the devel-
opment of airway obstruction in FD include loss of lung elastic
recoil, and airway inflammation and narrowing related to accu-
mulation of glycosphingolipid and hyperplasia in airway epithe-
lial and smooth muscle cells [57]. Thus, target cells partially
overlap with those in COVID-19. Obstructive lung disease was
present in 46% of patients with FD, this being up to 10-fold more
frequent than in the background population [58, 59].
MEDICATIONS COMMONLY USED IN THE
TREATMENT OF FD AND INTERACTION WITH
COVID-19
The interaction of COVID-19 with specific therapies for FD has
not been formally studied in patients with FD; however,
mechanism of action of these medications and any available
data is discussed in this section.
Renin–angiotensin system blockade
Many patients with FD are taking renin–angiotensin system
(RAS) blockers as antiproteinuric, nephroprotective and cardio-
protective agents [26]. Early in the course of the pandemic, there
was controversy on the benefit–risk balance of RAS blockade.
Since SARS-CoV-2 enters host cells by binding to ACE2 at the
cell membrane, and experimental animal data suggest that RAS
blockade could increase ACE2 expression in cardiovascular and
renal systems, it was hypothesized that treatment with angio-
tensin II receptor blockers (ARB) and angiotensin-converting en-
zyme inhibitors (ACEIs) might be deleterious by facilitating viral
entry into cells [60]. This hypothesis led patients and physicians
to stop ARBs/ACEIs, overlooking the alternative hypothesis that,
by increasing soluble ACE2 (sACE2), RAS blockade might be pro-
tective by providing a decoy receptor for SARS-CoV-2
(Supplementary data, Figure S1A). In clinical trials exploring re-
combinant human sACE2 to treat COVID-19, no evidence has
been found so far of either an adverse or beneficial effect of RAS
blockade on COVID-19, and scientific societies have emphasized
the risks of stopping RAS blockade [61–63]. A single manuscript
claiming a survival benefit for RAS blockade in COVID-19 has
been retracted [64].
ERT
Whether COVID-19 has an impact on the effectiveness of ERT
for FD is unknown, but some characteristics of SARS-CoV-2 in-
fection should be discussed. Agalsidase is internalized by endo-
cytosis from the extracellular space into endosomes through
cell surface receptors for mannose-6-phosphate (M6PR) as well
as through megalin or sortilin. The acidic pH of late endosomes
induces dissociation of the agalsidase–M6PR complexes, and
agalsidase is delivered to lysosomes, while the receptor is
recycled to the cell surface [65, 66]. A massive occupation of
endosomes by competitors or binding of other molecules to
their cognate receptors may interfere with the endocytic pro-
cess or downregulate receptors through their internalization
into lysosomes. Thus, both the SARS-CoV-2 and agalsidase
share a step of membrane fusion for cellular entrance and there
is potential competition between SARS-CoV-2 and ERT [67].
Chaperone therapy
Whether COVID-19 has an impact on the effectiveness of chap-
erone for FD is unknown. Much like ERT, there is also possible
competition between SARS-CoV-2 and a-galactosidase A en-
zyme coupled with the pharmacological chaperone [67].
COVID-19 THERAPY AND FD
Current therapy of COVID-19 is for the most part empirical and
based on treatment of disease symptoms [68]. Most medications
and therapies used to treat COVID, except for chloroquine and
hydroxychloroquine, do not have contraindications in patients
with FD; however, each medication should undergo a safety
profile review prior to initiating therapy in a patient with
FD [69].
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Antiviral therapy
This is aimed at interfering with viral cell entry into cells or viral
replication. Remdesivir has been found to shorten the time to
recovery in adults hospitalized with COVID-19 and evidence of
lower respiratory tract infection [70]. Additional antivirals or
drugs that potentially interfere with viral replication are or have
been commonly used include antivirals (e.g. lopinavir/ritonavir).
Although not specifically studied in FD, remdesivir is potentially
nephrotoxic and is not recommended in individuals with glo-
merular filtration rate <30 mL/min/1.73 m2 [71]. Otherwise,
there is no contraindication for remdesivir in FD [69].
Although no longer a preferred treatment option for COVID-
19, the early danger recognized in patients with FD using chlo-
roquine/hydroxychloroquine with its risks to inactivate Fabry-
specific therapies (ERT and chaperone therapy), prolong QT
intervals and trigger torsade de pointes underlines the impor-
tance of completing a safety assessment of investigational
treatment options [72–77].
Anti-inflammatory drugs
These medications are aimed at decreasing the adverse impact
of the cytokine storm. Drugs used so far include steroids, anti-
interleukin 6 (anti-IL-6) drugs (mainly tocilizumab) and janus ki-
nase inhibitors (such as baricitinib), which, together with other
approaches, are undergoing clinical trials [69]. Cytokines are
usually elevated in patients with FD at low but steady levels,
but how that impacts the risk of a cytokine storm during a
COVID-19 infection is unknown [78]. Tocilizumab and related
anti-IL-6 drugs have not been studied specifically in FD.
Anti-thrombotic strategies
This consists mainly of low molecular weight heparin for
COVID-19 patients including those not requiring admission.
There is no FD-specific contraindication for heparin; however,
many patients with FD may already be on aspirin, coumadin or
other anti-thrombotic medications.
Organ replacement/support
The need for oxygen therapy is a common indication for hospi-
tal admission. This treatment was used successfully in two
patients with FD in our data series. Beyond such supplementa-
tion, critical COVID-19 cases may need full cardiovascular, ven-
tilatory and kidney support or replacement, including
vasoactive drugs, ventilators or extracorporeal membrane oxy-
genation and RRT. Individuals with FD can be treated as their
disease state indicates with regards to oxygen, transplant and
life maintaining support. Living donors should be tested for FD
prior to transplant consideration [26, 69]. In several cities, hospi-
tals were overwhelmed by COVID-19 patients and access to in-
tensive care, ventilators or dialysis could not be guaranteed for
all those who needed it. This group strongly recommends that
diagnosis of FD should not be the basis for denying intensive
care, organ replacement or supportive therapy when indicated.
Peritoneal dialysis is an acceptable alternative when hemodial-
ysis or hemofiltration cannot be offered [79].
Convalescent plasma
COVID-19 convalescent plasma has been used to treat the dis-
ease [80]. One patient with critical COVID-19 and FD did have an
initial positive response to treatment early in disease course,
but it did not have a longer term positive impact on COVID-19
progression. There is no FD-specific contraindication for use of
convalescent plasma in patients with FD.
Exogenous pulmonary surfactant
The pathophysiological similarities between the infant respira-
tory distress syndrome and the lung involvement in COVID-19
have led clinicians to hypothesize that the administration of
pulmonary surfactant might be of help in patients with COVID-
19 requiring ventilator support; a clinical trial of nebulized sur-
factant therapy has been recently launched [81]. There is no FD-
specific contraindication for use of pulmonary surfactant in
patients with FD.
MITIGATING THE RISK OF SARS-COV-2
INFECTION IN FD WHILE CONTINUING ACCESS
TO SPECIFIC THERAPY
Clinical monitoring and enzyme replacement or chaperone ther-
apy are needed for optimal outcomes in FD [82]. In this regard,
the risk of developing COVID-19 should be weighed against the
risks of temporary interruption of ERT. Since the primary mode
of SARS-CoV-2 transmission is from person-to-person (through
respiratory droplets or direct and indirect contacts), patients
with FD should be advised to take preventive measures [83–85].
Additionally, healthcare institutions should also take measures
to provide healthcare safely. It is the authors’ opinion that for
most patients with FD, the benefits of continuing ERT without in-
terruption outweigh the risk of contracting SARS-CoV-2 at home
or in a secure healthcare setting [86].
Decreasing healthcare-associated risks
Healthcare facilities are enriched for both people more likely to
be currently infected and for individuals at higher risk for seri-
ous complications. It is likely that spread to employees in these
settings is increased [87]. While harder to study and demon-
strate, it is also likely that spread between patients is increased,
particularly in waiting rooms or other shared spaces. This has
led some patients with FD to conclude that the risk of exposure
to COVID-19 is high enough to consider interruption of treat-
ment and cancellation of evaluations. However, there are ways
to minimize this risk and these have been summarized in
International Organization for Standardization standards on
the topic [88].
• Telemedicine. During closures of physical medical centers
for in-person appointments and assessments at peak infec-
tion times, telemedicine appointments allow consultation
with key healthcare providers who can make the decision to
delay or continue specific assessments and treatments on
an individual basis.
• Home infusions are part of efforts to limit the need of
patients with FD to leave home without compromising
healthcare at the peak of the pandemic. They may decrease
the risk associated with transportation to and from infusion
centers. For this, the person administering the infusions
should strictly follow the recommended hygiene measures
and use appropriate personal protective equipment (PPE), in-
cluding mask, gloves and gowns, to minimize risk.
• Establishment of safe in-center infusion protocols. Risks can
be decreased in center-based care by use of masks, screening
employees and patients for fever and other COVID-19-
related symptoms, minimizing the number of people
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accompanying patients, rapid rooming, adequate airing and
use of appropriate hand washing and PPE [89]. The WHO has
published technical guidelines on infection prevention and
control and most institutions and out-patient centers have
instituted very strict infection control protocols resulting in
lower transmission rates [4]. A mixture of these measures
has been used in real-world experiences for FD therapy
(Supplementary data, Table S2).
Based on the authors’ clinical experience, patients with FD do
not seem to be at higher risk of becoming infected with the SARS-
CoV-2 than their household contacts and relatives without FD.
GENERAL APPROACH TO PREVENTION OF
COVID-19
Until a vaccine or a safe pre-exposure prophylaxis protocol are
developed, prevention of COVID-19 depends on social distanc-
ing, the use of face masks, hand washing and respiratory
hygiene.
Measures to prevent SARS-CoV-2 infection involve several
interrelated layers. Those involving actions by patients and
their families and those involving government intervention are
summarized in Supplementary data, Table S2. The main routes
of acquiring the virus in the community are via respiratory
droplets in the air or present on surfaces [85, 90]. It is now ac-
knowledged that the SARS-CoV-2 RNA can be detected in the
upper respiratory tract up to 5 days before symptoms develop
and asymptomatic individuals may transmit the disease [91].
Under pandemic conditions, everybody, including healthcare
personnel, should be considered potentially infectious and take
precautions.
Specific considerations for prevention of intrafamilial
transmission
Since FD is a genetic disease, multiple family members with FD
may be present in a single household [92]. Face mask use by the
primary case and family contacts before the primary case devel-
oped symptoms was 80% effective in reducing transmission, an
impact similar to daily use of chlorine or ethanol-based disin-
fectant in households [93]. However, wearing a mask after ill-
ness onset in the primary case was not significantly protective.
Although PCR positivity does not mean patients are infectious,
an additional consideration is that individuals with decreased
kidney function may remain viremic for longer than other
patients, with up to 90% of dialysis patients still PCR-positive a
median of 19 days post-diagnosis [94]. Patient #16 in our series
was PCR-positive 30 days post-diagnosis (Table 3). The recom-
mended time before contact with other FD family members
should be reviewed with a clinician prior to resumption.
CALL FOR AN INTERNATIONAL REGISTRY FOR
COVID-19 IN PATIENTS WITH FD
Management recommendations in this article are based on FD
experts’ experience with COVID-19 and individual case out-
comes. However, the rapidly evolving understanding of the im-
pact and treatment of COVID-19 requires clinicians caring for
patients with FD to adjust their patient care plans. Whether
patients with FD have an increased risk of SARS-CoV-2 infection
or of severe/critical COVID-19 remains an unsolved question.
Thus, it is important to systematically collect data regarding
exposures and confirmed infection to better inform optimal
management and assess potential risks to this population. To
compile as much data as possible to inform best practices, an
international registry for patients with FD infected by SARS-
CoV-2 should be established (Box 2). Such a registry would allow
scientists and clinicians to explore the impact of genetic varia-
tions that have been associated with more severe COVID-19 in
the general population [95–98]. It is also important to learn of
any repeat infections or COVID-19 antibody titers. Analysis of
this registry data will pave the way to providing information
based on real-time updated data about the impact of COVID-19
on patients living with FD and how to manage infected patients
across the disease spectrum.
CONCLUSIONS
Our limited data are insufficient to confirm or reject the hypothe-
sis that all patients with FD may be at increased risk of severe or
critical COVID-19. However, it appears that patients with ad-
vanced FD characterized by a kidney or cardiac transplant, use of
immunosuppressive medications and/or severe cardiovascular
complications may be at risk of severe or critical COVID-19 and
poor outcome, as is the case for individuals in the general popu-
lation. Given these theoretical considerations and the spectrum
of individual susceptibility to infection, it is wise that patients
with FD in the higher risk groups strictly comply with the SARS-
CoV-2 general safety precautions. Continued specific therapy for
FD during the pandemic is endorsed, even if it requires visits to a
medical center every 2 weeks for ERT administration, since its
benefits outweigh the perceived risk of developing COVID-19 in
secure healthcare settings. More data are needed to understand
infectivity, the manifestations and the natural history of SARS-
CoV-2 infection in patients with FD, but while evidence-based
recommendations are not available the need for strict adherence
to the protective guidelines issued by the WHO should be em-
phasized, especially hand hygiene, social distancing, airing and
face mask use [4]. Until a vaccine becomes available, keep on
guard for COVID-19 for the foreseeable future. Physicians caring
for patients with FD should be aware of the evolving local epide-
miological conditions and be especially careful in the autumn
and winter, when increased indoor activities and family gather-
ings may favor new waves of SARS-CoV-2 epidemic.
Box 1 Key messages for FD in the context of the
SARS-CoV-2 pandemic
• Currently, prevention of infection is the main current
weapon against SARS-CoV-2.
• The pathogenesis and target organs for COVID-19 shares
some features with FD.
• Pre-existent tissue injury may predispose patients with
advanced FD to a more severe course of COVID-19.
• Patients with FD should continue to receive full therapy
for FD, including ERT, chaperone therapy and/or renin–
angiotensin blockers.
• A diagnosis of FD should not preclude providing full ther-
apeutic and organ support as needed for patients with
severe or critical COVID-19.
• Some drugs used to treat COVID-19 may have a negative
safety profile for patients with prior heart conditions
and Fabry physicians should be consulted prior to
prescription.
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SUPPLEMENTARY DATA
Supplementary data are available at ckj online.
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